by Buck Institute
June 4, 2015 . Press Release
Serotonin receptor is involved in eczema and other itch conditions
Dermatologists have long known that available treatments for chronic itch, including eczema, are simply not up to scratch. But scientists have now discovered a new gene that promotes itch, suggesting a way forward for powerful new therapies. In a paper published June 11 in the early-online edition of Neuron, researchers at the Buck Institute for Research on Aging and the University of California, Berkeley have identified a serotonin receptor, HTR7, as a key mediator of eczema and other forms of itch. Eczema is a debilitating condition that affects up to 10 percent of the worldwide population. Its symptoms include intense itch sensations, dry flaky skin, and a flaming red rash. Eczema can erode quality of life as dramatically as chronic pain does, and is incurable, and treatments to manage eczema are often not effective. But now, the Buck/Berkeley team has identified a new gene that may accelerate development of chronic itch therapies.
The work involved a collaboration between UC Berkeley neuroscientist Diana Bautista, PhD, who runs a lab focused on the molecular basis of the sensations of itch, touch and pain, and Buck associate professor Rachel Brem, PhD, a geneticist who studies how and why traits differ between individuals. Bautista, Brem, and collaborators sought out genes whose expression was correlated with itch behavior across genetically distinct mouse strains. The serotonin receptor, HTR7, caught the scientists’ attention because the itchiest mice expressed the most HTR7 in the neurons that innervate the skin, and because abnormal serotonin signaling has long been linked to a variety of human chronic itch disorders, including eczema.
A battery of follow-up experiments then validated the role of HTR7 in chronic itch. In a mouse model of eczema, loss of the HTR7 gene in mice led to significantly less scratching and less severe skin lesions. “We are really excited about these results. The dramatic decrease in itching suggests that HTR7 may represent a new drug target for chronic itch,” said Bautista, who is an Associate Professor in the Department of Molecular and Cell Biology and a member of the Helen Wills Neuroscience Institute at UC Berkeley.
Brem says that, in addition to eczema, altered serotonin signaling in the skin is found in other forms of itch, including psoriasis and allergic itch. Therefore, the new findings hold promise for treatment of many itch disorders. In fact, in humans, itching and scratching can be side effects of taking antidepressants, which can elevate levels of serotonin in the skin. In the Buck/UC Berkeley study, this side effect was observed in mice, too—the drug Zoloft caused intense scratching, which vanished when HTR7 was ablated. Given that in humans HTR7 is also expressed in the neurons that innervate the skin, this new gene may well be responsible for itch in human patients taking antidepressants.
“An estimated 10 – 20 percent of the population will suffer from chronic itch at some point in their lifetime,” said Brem. “In addition to eczema, chronic itch can stem from systemic conditions including kidney failure, cirrhosis and some cancers. Understanding the molecular basis of chronic itch is of significant clinical interest, and now there is a new target available to explore.”
Citation: Neuron: HTR7 mediates serotonergic acute and chronic itch
Other collaborators include: Takeshi Morita, Shannan P. McClain, Lyn M. Batia, Maurizio Pellegrino, Sarah R. Wilson, and Justin F. Wong, all from the University of California, Berkeley; as well as Michael A. Kienzler, Kyle Lyman, and Anne Sofie Braun Olsen from the Neurobiology Summer course at the Marine Biological Laboratory at Woods Hole, MA; and Cheryl L. Stucky from the Medical College of Wisconsin in Milwaukee. This work was supported by National Institutes of Health grants AR059385, DOD007123A, NS084812, and NS077224 and a National Science Foundation Fellowship. This work used the Vincent J. Coates Genomics Sequencing Laboratory at UC Berkeley, supported by NIH S10 Instrumentation Grants S10RR029668 and S10RR027303. This work also used the Biological Imaging Facility, supported by NIH grant 1S10RR026866-01.
Science is showing that while chronological aging is inevitable, biological aging is malleable. There's a part of it that you can fight, and we are getting closer and closer to winning that fight.
Eric Verdin, MD, Buck Institute President and CEO